Carna Biosciences, Inc. (TYO:4572)
310.00
-7.00 (-2.21%)
Nov 18, 2026, 10:13 AM JST
Carna Biosciences Revenue
Carna Biosciences had revenue of 172.00M JPY in the quarter ending September 30, 2026, with 19.17% growth. This brings the company's total for the last twelve months to 756.57M, up 38.96% year-over-year. In the year 2025, Carna Biosciences had annual revenue of 579.00M, down -8.96%. That makes Carna Biosciences the 40,184th largest company in the world by revenue and 3,814th in Japan.
Revenue (ttm)
756.57M
Revenue Growth
+38.96%
P/S Ratio
9.71
Revenue / Employee
12.40M
Employees
61
Market Cap
7.25B
Revenue by Geography
- United States of America 259.61M 44.8%
- Japan 169.19M 29.2%
- China 96.55M 16.7%
- Europe 47.71M 8.2%
- Others 5.99M 1.0%
Fiscal year ended Dec 31, 2025 See the full Carna Biosciences breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 579.00M | -57.00M | -8.96% |
| Dec 31, 2024 | 636.00M | -989.00M | -60.86% |
| Dec 31, 2023 | 1.63B | 239.00M | 17.24% |
| Dec 31, 2022 | 1.39B | -631.00M | -31.28% |
| Dec 31, 2021 | 2.02B | 884.00M | 78.02% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Kidswell Bio | 5.79B |
| StemCell Institute | 2.81B |
| Immuno-Biological Laboratories | 1.08B |
| OncoTherapy Science | 712.00M |
| Nano Holdings | 210.00M |
| CellSeed | 161.00M |
| ADR Biomedical Holdings | 98.00M |
| Kubota Pharmaceutical Holdings | 12.77M |